Efsitora Dosing and Titration in Type 2 Diabetes

Once-weekly basal insulin is now a two-product class in the US, and the newest entrant, insulin efsitora alfa-gobe (Onswik), brings a dosing framework distinct from familiar daily basal practice.

On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed the US Food and Drug Administration (FDA)’s approval of efsitora for adults with type 2 diabetes and its labeled titration strategies. The September 24, 2026, approval rests on the four phase 3 QWINT trials and follows the March 2026 approval of insulin icodec (Awiqli).

Watch the full episode discussing the FDA’s approval of efsitora alfa-gobe here.

Dose capacity is a central practical feature. A 400-unit weekly dose equates to roughly 57 units per day, adequate for many patients, while a U-1000 formulation extends dosing for people with marked insulin resistance.

The prescribing information offers two titration approaches drawn from the trial designs. The fixed-dose schedule starts at 100 units weekly, then steps to 150, 250, and 400 units at intervals of at least four weeks while fasting glucose remains above 130 mg/dL. These increments exceed typical daily basal adjustments, and beyond 400 units, titration proceeds in 20- to 40-unit weekly steps.

The flexible schedule relies on a loading dose. With a half-life of roughly 17 days, efsitora would reach target far more slowly without one. Week one therefore begins at 300 units, week two drops to 100 units, and later doses shift by 20 to 40 units based on glucose.

For patients switching from glargine or degludec, clinicians multiply the total daily dose by seven for the weekly equivalent and triple it for the first week. Subsequent weeks revert to the sevenfold conversion with the same 20- to 40-unit adjustments.

Hypoglycemia remains the principal adverse effect, as with any insulin, and dose reduction is advised when it occurs. Several QWINT trials captured continuous glucose monitoring outcomes, adding insight into glycemic variability beyond A1c reduction.

Weekly administration suits patients who struggle with daily injections or depend on caregivers, including older adults who could receive basal insulin alongside a weekly glucagon-like peptide-1 receptor agonist during a single visit. The availability of two concentrations and two titration pathways gives clinicians room to individualize therapy as experience with weekly basal insulin grows.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

References

1. Rosenstock J, Bailey T, Connery L, et al. Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. N Engl J Med. 2025;393(4):325-335. doi:10.1056/NEJMoa2502796

2. Philis-Tsimikas A, Bergenstal RM, Bailey TS, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. Lancet. 2025;405(10497):2279-2289. doi:10.1016/S0140-6736(25)01044-X

3. Blevins T, Dahl D, Pérez Manghi FC, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet. 2025;405(10497):2290-2301. doi:10.1016/S0140-6736(25)01069-4